Method for predicting the risk of developing side effects due to administration of compounds whose own or intermediate metabolites are metabolized by the UGT1A1 enzyme

摘要

A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan; and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drug reaction , thereby reducing the adverse drug reaction cased by the administration of irinotecan. IMAGE